Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
Thor-Henrik Brodtkorba RTI Health Solutions, Ljungskile, Sweden
https://orcid.org/0000-0002-9899-233XView further author information
https://orcid.org/0000-0002-9899-233XView further author information, , , Siguroli Teitssonc Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]
https://orcid.org/0009-0001-7378-1675View further author information
https://orcid.org/0009-0001-7378-1675View further author information, , Miraj Y. Pateld Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0002-3543-1420View further author information
https://orcid.org/0000-0002-3543-1420View further author information, , & Stephen Palmerf Centre for Health Economics, University of York, York, UKhttps://orcid.org/0000-0002-7268-2560View further author information
https://orcid.org/0000-0002-7268-2560View further author information show all